Breaking News Instant updates and real-time market news.

REPH

Recro Pharma

$7.47

-0.02 (-0.27%)

07:03
07/31/17
07/31
07:03
07/31/17
07:03

Recro Pharma submits new drug application for IV Meloxicam 30mg

Recro Pharma announced it has submitted a NDA to the FDA for its lead investigational product candidate intravenous meloxicam 30mg for the treatment of moderate to severe, acute postoperative pain. The IV meloxicam 30mg NDA is supported by positive results from two pivotal Phase III clinical efficacy trials in patients following bunionectomy and abdominoplasty surgeries, a large double-blind Phase III safety trial and four Phase II clinical trials for the management of moderate to severe postoperative pain, among others.

REPH Recro Pharma
$7.47

-0.02 (-0.27%)

11/28/16
ROTH
11/28/16
NO CHANGE
Target $24
ROTH
Buy
Recro Pharma IV meloxicam is approvable, says Roth Capital
Roth Capital analyst Scott Henry notes that Recro Pharma announced the second positive efficacy trial for IV meloxicam to treat post-surgical acute pain, and confirmed its target for a summer 2017 NDA filing with few major hurdles likely remaining. The analyst believes IV meloxicam is approvable and could represent an alternative to opioid pain medications. Henry reiterates a Buy rating and $24 price target on the shares.
12/19/16
PIPR
12/19/16
INITIATION
Target $12
PIPR
Overweight
Recro Pharma initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst David Amsellem started Recro Pharma with an Overweight rating and $12 price target. The company's injectable form of the non-steroidal anti-inflammatory drug meloxicam for post-surgical pain, N1539, has the potential to drive "transformational cash generation" over the long-term, Amsellem tells investors in a research note.
12/19/16
12/19/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Harley-Davidson (HOG) initiated with a Neutral at Goldman. 2. Anadarko (APC) initiated with a Buy at Ladenburg. 3. Baidu (BIDU) initiated with an Underweight at Cantor. 4. Recro Pharma (REPH) initiated with an Overweight at Piper Jaffray. 5. B&G Foods (BGS) initiated with a Neutral at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/17
ROTH
03/07/17
NO CHANGE
Target $20
ROTH
Buy
Recro Pharma price target lowered to $20 from $24 at Roth Capital
Roth Capital analyst Scott Henry lowered his price target for Recro Pharma to $20 from $24 after quarterly results. The analyst believes the company remains on target for an NDA filing for IV Meloxicam to treat acute pain this summer, and reiterates a Buy rating on the shares.

TODAY'S FREE FLY STORIES

VIPS

Vipshop

$9.25

-0.53 (-5.42%)

16:07
11/20/17
11/20
16:07
11/20/17
16:07
Earnings
Breaking Earnings news story on Vipshop »

Vipshop sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

A

Agilent

$69.92

1.125 (1.64%)

16:06
11/20/17
11/20
16:06
11/20/17
16:06
Earnings
Agilent reports Q4 adjusted EPS 67c, consensus 62c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 30

    Nov

VIPS

Vipshop

$9.27

-0.51 (-5.21%)

16:06
11/20/17
11/20
16:06
11/20/17
16:06
Earnings
Vipshop reports Q3 adjusted EPS 14c, consensus 14c »

Reports Q3 revenue $2.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

ARNC

Arconic

$23.87

0.02 (0.08%)

16:05
11/20/17
11/20
16:05
11/20/17
16:05
Hot Stocks
Arconic to install new horizontal heat treat furnace at Davenport Works facility »

Arconic announced plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$157.78

1.23 (0.79%)

16:05
11/20/17
11/20
16:05
11/20/17
16:05
Earnings
Intuit reports Q1 EPS (7c), consensus (5c) »

Reports Q1 revenue $886M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SIFI

SI Financial

$14.95

0.35 (2.40%)

16:04
11/20/17
11/20
16:04
11/20/17
16:04
Hot Stocks
SI Financial Chief Credit Officer Gerald Coia to retire »

SI Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENTA

Enanta

16:03
11/20/17
11/20
16:03
11/20/17
16:03
Earnings
Enanta Pharmaceuticals reports Q4 EPS $1.86, consensus $2.13 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

NBIX

Neurocrine

, ZBH

Zimmer Biomet

$112.03

0.42 (0.38%)

16:02
11/20/17
11/20
16:02
11/20/17
16:02
Hot Stocks
Neurocrine names Matt Abernethy as CFO »

Neurocrine Biosciences…

NBIX

Neurocrine

ZBH

Zimmer Biomet

$112.03

0.42 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 01

    Dec

  • 14

    Dec

CAFD

8point3 Energy

$14.94

0.04 (0.27%)

, PEGI

Pattern Energy

$22.13

0.14 (0.64%)

15:46
11/20/17
11/20
15:46
11/20/17
15:46
Periodicals
8point3 draws interest from Capital Dynamics, Pattern Energy, Bloomberg says »

Capital Dynamics and…

CAFD

8point3 Energy

$14.94

0.04 (0.27%)

PEGI

Pattern Energy

$22.13

0.14 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

VRX

Valeant

$15.64

0.95 (6.47%)

15:40
11/20/17
11/20
15:40
11/20/17
15:40
Options
Valeant calls active as shares see relative strength »

Valeant calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Jun

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

, GIS

General Mills

$54.23

0.51 (0.95%)

15:34
11/20/17
11/20
15:34
11/20/17
15:34
Periodicals
General Mills, not Nestle, should buy Hain Celestial, Cramer says »

Following a Bloomberg…

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

GIS

General Mills

$54.23

0.51 (0.95%)

NSRGY

Nestle

$85.11

0.7 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$156.55

0.9 (0.58%)

15:34
11/20/17
11/20
15:34
11/20/17
15:34
Options
Intuit options imply 5.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SHPG

Shire

$147.37

2.74 (1.89%)

, RHHBY

Roche

$29.10

0.205 (0.71%)

15:32
11/20/17
11/20
15:32
11/20/17
15:32
Recommendations
Shire, Roche analyst commentary  »

Shire selloff on Roche…

SHPG

Shire

$147.37

2.74 (1.89%)

RHHBY

Roche

$29.10

0.205 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 23

    Dec

  • 23

    Feb

15:30
11/20/17
11/20
15:30
11/20/17
15:30
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

TWX

Time Warner

$87.93

-0.79 (-0.89%)

15:28
11/20/17
11/20
15:28
11/20/17
15:28
Technical Analysis
Technical View: Time Warner drops on pending antitrust briefing »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$34.74

0.23 (0.67%)

, TWX

Time Warner

$87.93

-0.79 (-0.89%)

15:28
11/20/17
11/20
15:28
11/20/17
15:28
Periodicals
DOJ antitrust announcement concerns AT&T, Time Warner, NBC reports »

Bloomberg also reported…

T

AT&T

$34.74

0.23 (0.67%)

TWX

Time Warner

$87.93

-0.79 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

MRVL

Marvell

$20.29

0.03 (0.15%)

, CAVM

Cavium

$75.83

-0.47 (-0.62%)

15:27
11/20/17
11/20
15:27
11/20/17
15:27
Recommendations
Marvell, Cavium, Broadcom analyst commentary  »

Marvell price target…

MRVL

Marvell

$20.29

0.03 (0.15%)

CAVM

Cavium

$75.83

-0.47 (-0.62%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 06

    Dec

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

15:24
11/20/17
11/20
15:24
11/20/17
15:24
Technical Analysis
Technical View: Hain Celestial spikes higher, retraces some gains »

The shares have come off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

, NSRGY

Nestle

$85.11

0.7 (0.83%)

15:22
11/20/17
11/20
15:22
11/20/17
15:22
Hot Stocks
Hain Celestial surges after report of Nestle weighing potential bid »

Shares of Hain Celestial…

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

NSRGY

Nestle

$85.11

0.7 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$56.11

1.07 (1.94%)

15:20
11/20/17
11/20
15:20
11/20/17
15:20
Options
Sarepta Therapeutics sees a bullish option play »

Sarepta Therapeutics sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

HAIN

Hain Celestial

$40.06

0.21 (0.53%)

15:19
11/20/17
11/20
15:19
11/20/17
15:19
Hot Stocks
Breaking Hot Stocks news story on Hain Celestial »

Hain Celestial trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRG

HRG Group

$16.06

-0.025 (-0.16%)

15:19
11/20/17
11/20
15:19
11/20/17
15:19
Options
Harbinger options imply 8.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

, NSRGY

Nestle

$85.11

0.7 (0.83%)

15:17
11/20/17
11/20
15:17
11/20/17
15:17
Hot Stocks
Breaking Hot Stocks news story on Hain Celestial, Nestle »

Hain Celestial jumps 7%,…

HAIN

Hain Celestial

$39.84

1.35 (3.51%)

NSRGY

Nestle

$85.11

0.7 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
11/20/17
11/20
15:17
11/20/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
11/20/17
11/20
15:16
11/20/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.